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Abstract 
 KRAS-mutation is a key driver of pancreatic cancer and PI3K pathway activity is an 
additional requirement for Kras-induced tumorigenesis. Clinical trials of PI3K pathway 
inhibitors in pancreatic cancer have shown limited responses. Understanding the molecular 
basis for this lack of efficacy may direct future treatment strategies with emerging PI3K 
inhibitors. We sought new therapeutic approaches that synergise with PI3K inhibitors 
through pooled CRISPR modifier genetic screening and a drug combination screen. ERBB-
family receptor tyrosine kinase signalling and mTOR signalling were key modifiers of 
sensitivity to alpelisib and pictilisib. Inhibition of the ERBB-family or mTOR was synergistic 
with PI3K inhibition in spheroid, stromal co-cultures. Near-complete loss of ribosomal S6 
phosphorylation was associated with synergy. Genetic alterations in the ERBB-PI3K 
signalling axis were associated with decreased survival of pancreatic cancer patients. 
Suppression of the PI3K/mTOR axis is potentiated by dual PI3K and ERBB family or mTOR 
inhibition. Surprisingly, despite the presence of oncogenic KRAS, thought to bestow 
independence from receptor tyrosine kinase signalling, inhibition of the ERBB family blocks 
downstream pathway activation and synergizes with PI3K inhibitors. Further exploration of 
these therapeutic combinations is warranted for the treatment of pancreatic cancer. 
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Introduction 
 The 10-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has 
remained at just 3 % for the past 40 years (1). Activation of the oncogene, KRAS, is one of 
the earliest genetic alterations detected in the development of PDAC and KRAS mutations 
are found in over 90 % of cases (2,3). Transgenic mouse models expressing oncogenic 
KrasG12D have demonstrated that mutant KRAS is an important driver in pancreatic cancer, 
as switching off Kras signalling results in tumour regression (4). Recently discovered 
inhibitors of KRAS12C have further validated the dependency of pancreatic, colon and lung 
tumor models on oncogenic KRAS and demonstrated promising early clinical activity (5,6). 
There is a strong rationale for targeting PI3K in PDAC. Activation of the PI3K 
pathway is commonly observed in PDAC patient samples (7-9),  regulates cell metabolism, 
growth and survival and is commonly implicated as a driver of human cancer (10). 
Importantly, phosphorylation of PI3K signalling markers, including AKT (Ser473), mTOR 
(Ser2448) and GSK3β (Ser9) (11) or low expression of PTEN, a suppressor of PI3K 
signalling (12), is predictive of poor survival in pancreatic cancer. Moreover, the interaction 
between Ras and PI3Kα is essential for KrasG12D-induced tumorigenesis in mice (13). 
Notably, KrasG12D-driven murine PDAC tumours are dependent on PI3Kα (14,15) but not 
PI3Kβ (15), or Craf (14) for tumorigenesis. Consequently, PI3K signalling is an attractive 
therapeutic target for PDAC. However, clinical trials of allosteric mTOR inhibitors, including 
temsirolimus (7), or everolimus (16), have shown limited activity in gemcitabine-refractory, 
metastatic pancreatic cancer patients, likely due to loss of negative feedback on IRS1 and 
reactivation of PI3K (16). Multiple oncogenic pathways are engaged downstream of KRAS 
(17,18), so it is perhaps unsurprising that targeting a single downstream effector may not be 
enough to affect cell viability. We hypothesise that PI3K inhibition selects for compensatory 
mechanisms sufficient to maintain tumour cell survival. 
This study aimed to elucidate the mechanisms of intrinsic resistance to PI3K 
inhibition in pancreatic cancer and identify rational drug combinations to overcome them. 
Functional genomic screens have successfully identified loss-of-function events that drive 
drug resistance, finding NF1 loss to be a key driver of resistance to RAF inhibition in 
melanoma (19).  We therefore employed a genome-scale synthetic lethal CRISPR screen to 
find loss of function events that could modulate sensitivity to PI3K inhibition. We discovered 
that the ERBB and mTOR signalling networks regulate response to PI3K inhibition in PDAC. 
Furthermore, we used a combination drug screen to prioritise clinically relevant targeted 
agents that synergise with PI3K inhibition to improve therapeutic response. 
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Materials and Methods 
Cell lines and cell culture 
  Pancreatic cancer cell lines were a kind gift from Dr Anguraj Sadanandam (The 
Institute of Cancer Research), with the exception of PANC1, PATU8902, MIAPACA2, YAPC 
and HEK293T cells, which were obtained from the American Tissue Culture Collection 
(ATCC). T47D cells were from the Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ). All cells were cultured in Dulbecco's Modified Eagle Medium (Sigma) 
supplemented with 10 % Fetal Bovine Serum (FBS Good, Pan Biotech), with the exception 
of MIAPACA2 which was supplemented with 20 % FBS. Human pancreatic stellate cells 
(PSC) were obtained from ScienCell laboratories. Recombinant growth factors were 
obtained from Bio-Techne. Cell lines were tested for mycoplasma using the MycoAlert 
Mycoplasma Detection Kit (Lonza). Cell line authentication was not performed. 
Small molecule inhibitors 
All small molecule inhibitors were purchased from Selleck Chemicals: BYL719 
(S2814), GDC0941 (S1065), pelitinib (S1392), everolimus (S1120), AZD8055 (S1555), 
AZD2014 (S2783) and BEZ235 (S1009). Stock solutions were prepared in dimethylsulfoxide 
(DMSO) and stored at -20°C.  
Cell proliferation assays 
 For GI50 determinations, cells were seeded in 96 well plates. The next day, cells 
were treated with increasing concentrations of inhibitor or with DMSO alone. After a 72 h 
incubation period, cell proliferation was quantified using CellTiter-Blue reagent (Promega) 
and normalised to DMSO treated wells. GI50 values were calculated using non-linear 
regression analysis in GraphPad Prism software. For population doubling experiments, cells 
were seeded at an initial density of 1x107 cells/flask in 225 cm2 flasks. Cells were allowed to 
proliferate to 80-90 % confluence before they were counted and then reseeded at the same 
initial density. Population doublings (PD) were calculated according to the equation below.  
 
For determination of maximum excess above bliss, cells were treated with a matrix of 
increasing concentrations of two inhibitors or DMSO.  After a 72 h incubation period, cell 
proliferation was quantified using CellTiter-Blue reagent and normalised to the DMSO 
treated well. The Bliss independence model (20) was used to calculate synergy.  
Population doublings = Log (cell count/initial cell number) 
Log (2) 
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 For colony assays, cells were seeded in 12 well plates. The next day, triplicate wells 
were treated with DMSO, the inhibitors alone or the combinations. After 14 d, cells were 
washed with PBS and fixed in 4 % formaldehyde/PBS for 30 min. Cells were stained with 0.5 
% crystal violet in 70 % ethanol and imaged using a FluoroChem E imaging system (Protein 
Simple). Colonies were quantified by solubilising the crystal violet solution in 10 % acetic 
acid and reading the absorbance at 595 nm using an EMax® Plus Microplate Reader 
(Molecular Devices). 
Spheroid growth assays 
Human pancreatic stellate cells (PSC) were cultured in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham (Sigma Aldrich), supplemented with 1 % GlutaMAX 
(ThermoFisher Scientific), 1 % Amphotericin B (ThermoFisher Scientific), 1 % Penicillin-
Streptomycin (Sigma Aldrich) and 10 % Fetal Bovine Serum (FBS Good, Pan Biotech). Cells 
were seeded in co-culture with established PDAC cell lines at a starting density of 1x103 
cells/well in 96 well Ultra-low Attachment Round Bottom Multi-well Plates (Nexcelom). Cells 
were seeded to form spheroids at a ratio of 1:1 PSCs to PDAC cell lines. The next day, cells 
were treated with DMSO, fixed concentrations of drugs or the desired combinations. 
Spheroid diameter was measured over a time period of 10 d, with measurements taken 
every 3-4 d. The first measurement was taken the day after cells were plated, before the 
addition of DMSO and drug treatments. Spheroid diameter was imaged and quantified using 
the Celigo Imaging Cytometer (Nexcelom) and is the average of at least 3 replicate 
spheroids. For viability staining, spheroids were incubated with 1 µM calcein AM and 40 
µg/ml propidium iodide for 30 min prior to imaging. 
Cell lysis and Western blotting 
After the desired treatment, cells were washed with cold PBS and lysed in NP40 
buffer (0.5 % NP40, 150 mM NaCl, 50 mM Tris pH7.5, Pierce Protease and Phosphatase 
Inhibitor Mini Tablets (Life Technologies)). Where detection of KRAS was necessary, cells 
were lysed in SDS buffer (1 % SDS, 10 mM EDTA, 50 mM Tris, pH 8). Bicinchoninic acid 
(Sigma) was used to determine protein concentration. Equal amounts of protein were 
separated by gel electrophoresis, using NuPAGE polyacrylamide gels (Life Technologies). 
Proteins were transferred to a nitrocellulose membrane using the iBlot 2 system (Life 
Technologies) and then blocked with LI-COR blocking buffer (LI-COR Biosciences). 
Membranes were incubated with the primary antibodies overnight at 4 °C, followed by 
IRdye-conjugated secondary antibodies (LI-COR Biosciences) and detected using an 
Odyssey Fc imaging system (LI-COR Biosciences). Quantification of Western blots was 
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performed using Image Studio Lite (LI-COR Biosciences).  Details of the antibodies used 
can be found in Table S1. 
Lentiviral production 
HEK293T cells were seeded at a density of 2.4 x106 cells/plate in 10 cm plates. The 
next day cells were transfected with shRNA/sgRNA plasmid (3 µg) and the packaging 
plasmids psPAX2 (2.1 µg) and pmD2.G (0.9 µg) using 30 µl lipofectamine per transfection. 
Cells were incubated for 72 h at 37 °C, after which the supernatant was collected and stored 
in 0.5 ml aliquots at -80 °C for future experiments. Each batch of lentivirus was titrated on 
cells to determine concentration needed for 100 % infection efficiency. 
shRNA  
MISSION shRNA plasmids (pLKO.1) were obtained from Sigma-Aldrich. The 
pLKO.1-LacZ and -Luciferase targeting shRNA plasmids were from the Genetic Perturbation 
Platform (The Broad Institute). TRC numbers and target sequences for shRNA plasmids are 
shown in Table S2. Cells were transduced with lentivirus as previously described (19). Cell 
proliferation was quantified using CellTiter-Blue reagent (Promega) and normalised to cells 
transduced with control lentivirus. Gene dependency scores were calculated based on the 
dependency index described by Singh et al. (21).  
Drug combination screen 
Cells were plated in 384 well plates and the Echo 550 Liquid Handler (Labcyte) was 
used to dispense 20 nl of each compound from a library of 485 Food and Drug 
Administration approved drugs and tool compounds (selected by the Cancer Research UK 
Cancer Therapeutics Unit and purchased from Selleckchem) onto the plates to give the final 
concentration of 800 nM on the cells. Plates were then treated with either 100 nl of DMSO, 
BYL719 or GDC0941, to give a final concentration of 10 μM BYL719 or 1 µM GDC0941. 
After a 96 h incubation period, cell proliferation was quantified using CellTiter-Blue reagent 
(Promega). Synergy was calculated using the Bliss independence model, as previously 
described. The Bliss score for each combination is the mean of three replicates.  
CRISPR 
LentiCRISPRv2 (was a gift from Feng Zhang, Addgene plasmid #52961) (22) were 
digested with Esp3I at 37 °C overnight (New England Biolabs, NEB). Oligos were designed 
to include each sgRNA target sequence (Table S3) according to the “Zhang Lab General 
Cloning Protocol”, available at https://www.addgene.org/crispr/zhang/. Each pair of oligos 
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was phosphorylated and annealed with T4 PNK enzyme (NEB). Each oligo duplex was then 
ligated into the appropriate vector using the quick ligase enzyme (NEB) at 16 °C overnight. 
Lentiviral plasmids were transformed into Stbl3 bacteria (Invitrogen), according to the 
manufacturer’s instructions and then plated on ampicillin (50 mg/ml)-selective agar plates. 
Single colonies were then amplified, extracted and used to produce lentivirus as described 
above. Before generation of lentivirus, each amplified plasmid was sequenced to ensure 
successful sgRNA sequence integration. To generate clonal cell populations expressing 
each plasmid, cells were first transduced with the virus. Cells were transduced with the 
lentiCRISPRv2 lentivirus, as this also contains the vector for Cas9 expression. Cells 
successfully transduced with lentiCRISPRv2 were selected for using 10 µg/ml blasticidin, 
respectively. After 7 d of selection, cells were seeded in 96 well plates at a density of 0.5 
cells/well to select for clonal populations. These were expanded under continued antibiotic 
selection until sufficient cell numbers were generated. Stocks were frozen down in FBS with 
10 % DMSO and stored in liquid nitrogen.  
Generation of Cas9 cell lines 
Cell lines were engineered to express Cas9 by centrifugation of 4x106 cells with 
(pXPR101) Cas9 lentivirus (1:1), in the presence of 8 μg/ml polybrene for 1 h at 37 °C. Cells 
were incubated with fresh media overnight, before cells were trypsinized and pooled for 
selection. Cells were incubated with 10 μg/ml blasticidin for 7 d to select for successfully 
infected cells. In parallel, cells were plated in 6 well plates for determination of infection 
efficiency. To assess Cas9 activity, parental and Cas9 expressing cells were infected with a 
lentivirus encoding both EGFP and a sgRNA targeting EGFP (pXPR_011-sgEGFP). 
Successfully transduced cells were selected for using 2 μg/ml puromycin, until all cells of a 
‘no infection control’ were dead. Cells were assayed by flow cytometry to assess EGFP 
expression. The activity of Cas9 was taken as the proportion of EGFP negative cells in the 
Cas9 transduced population.  
Genome-wide synthetic lethal screen protocol 
Cells were seeded in 12 well plates at a density of 3x106 cells/well in 2 ml media. 
Cells were infected with the Avana4 lentiviral library (Broad Institute, 74,687 sgRNAs 
targeting 18,407 genes, (23,24)) in four infection replicates. Cells were infected with a 
predicted representation of 500 cells/sgRNA after selection and with the volume of virus/well 
that gave ~40 % infection efficiency. Cells were centrifuged at 2000 rpm for 2 h at 30 °C in 
the presence of lentivirus and 8 μg/ml polybrene, followed by incubation in fresh media 
overnight. Cells were pooled and seeded into T225 flasks at a density of 1x107 cells/flask for 
selection with 2 μg/ml puromycin for 7 d and passaged as necessary. In parallel, cells were 
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seeded in 6 well plates to determine infection efficiency. After 7 d of selection, MIAPACA2 
cells were split into three arms and treated with either 0.02 % DMSO, 10 µM BYL719 or 1 
µM GDC0941. Throughout the screen cells were passaged as necessary, maintaining a total 
representation of 500 cells/sgRNA in each replicate. After 8 population doublings, cells from 
each arm were collected and cell pellets stored at -80 °C. Genomic DNA was extracted 
using the QIAamp DNA Blood Maxi Kit (Qiagen). PCR amplification and next generation 
sequencing was conducted as previously described (23). Briefly, sequencing adaptors and 
sample barcodes were added to sgRNA sequences from gDNA and pDNA samples by PCR. 
Samples were purified with Agencourt AMPure XP SPRI beads (Beckman Coulter A63880) 
and then sequenced on a HiSeq2000 (Illumina). Reads were counted by searching for the 
CACCG sequence of each sgRNA insert and then mapping the 20 nucleotide sgRNA 
sequence to a reference file of all sgRNAs in the library and assigned to the treatment 
condition based on the appended barcode.  
Focussed minipool screen protocol 
The custom minipool lentiviral library (3,067 sgRNAs targeting 296 top hit genes (one 
gene was accidentally omitted), 496 non-targeting control sgRNAs and 201 sgRNAs 
targeting essential genes) was prepared as previously described (23,24). Plasmid DNA 
(pDNA) was sequenced by next-generation sequencing (NGS) to quantify the abundance of 
each sgRNA in the pool. The pDNA pool was then transfected into HEK 293T cells to 
produce lentivirus according to the “Large Scale Lentiviral Production” protocol available at 
https://portals.broadinstitute.org/gpp/public/resources/protocols. Each cell line was infected 
with the custom minipool lentiviral library in four infection replicates. Cells were infected with 
a predicted representation of 2000 cells/sgRNA, after selection, and with the volume of 
virus/well that gave ~40 % infection efficiency, as determined previously. The transduction 
and selection protocol used was the same as in the genome-wide screen and is described 
above. After 7 d of selection, cells were split into three arms and treated with either 0.02 % 
DMSO, BYL719 or GDC0941. Throughout the screen cells were passaged to maintain a 
representation of 2000 cells/sgRNA. After 8 population doublings, cells from each arm were 
collected and genomic DNA was extracted and sequenced, as in the whole-genome screen.  
CRISPR screen analysis   
The abundance of each sgRNA in each replicate was quantified by calculating the 
Log2(sequencing reads/million) (RPM), according to the formula below. 
 
RPM = Log2 (((reads per sgRNA/total reads per condition) × 10
6) +1) 
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The log2 fold change (LFC) from the early time point was calculated by normalising 
RPM for each sgRNA in each replicate to that in an early time point control taken 3 d after 
selection with puromycin. The LFC between the DMSO and drug treated arms was 
calculated as the difference in average LFC across 3 replicates. This was used to rank 
individual sgRNAs according to their selective depletion or enrichment in the drug treated 
arms. Top scoring genes were ranked according to the number of independent high scoring 
sgRNAs targeting the same gene, according to the STARS gene-ranking algorithm (23). In 
order to assess depletion of essential genes from the population, as a positive control for 
successful gene editing, the RPM for each sgRNA was normalised to the plasmid DNA to 
calculate the LFC from baseline. The list of 885 core essential genes was kindly provided by 
Dr Marco Licciardello (The Institute of Cancer Research) and is compiled from the genes 
that were consistently and significantly depleted in all cell lines tested from three previous 
publications (25-27). To assess the statistical significance of the overlap between genes that 
modulated the response to BYL719 or GDC0941, the representation factor was calculated 
as below. 
The associated probability was calculated by exact hypergeometric probability as detailed at 
http://nemates.org/MA/progs/representation.stats.html.  
Gene set enrichment analysis of genome-wide screen 
A list of all hit genes was compiled from those that were that were enriched or 
depleted from the BYL719 or GDC0941 treated arms of the genome-wide CRISPR screen 
(FDR <0.3). This list was used to interrogate the Reactome (28) and KEGG (29,30) gene 
sets within the Molecular signatures database (31,32), available at 
http://software.broadinstitute.org/gsea/msigdb. 
Results  
Loss of function CRISPR screen in PDAC cells identifies RTK and mTOR signalling 
networks as key determinants of response to PI3K inhibition 
To discover loss of function events that modulate sensitivity to PI3K inhibition in 
PDAC we conducted a genome-wide CRISPR screen anchored to the PI3Kα-selective 
inhibitor BYL719 (alpelisib)(33) or the pan-class I PI3K inhibitor GDC0941 (pictilisib)(34). In 
vitro, pancreatic cell lines were resistant to BYL719 and GDC0941, compared to the PI3Kα-
Representation factor =  # genes in common 
                          expected # of genes 
Expected # of genes = (# genes in group 1 * # genes in group 2) 
                             Total number of genes tested 
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dependent breast cancer cell line, T47D (Figure 1A, S1A)(35). Resistance was observed 
despite inhibition of PI3K-AKT signalling, highlighting a disconnect between pathway 
inhibition and inhibition of cell proliferation in the pancreatic cells (Figure 1B, S1E). We 
selected MIAPACA2 cells for the genome-wide screen, as they were resistant to both 
BYL719 and GDC0941 and dependent on KRAS for proliferation (Figure S1A-C). We 
engineered this cell line to stably express Cas9 (MIAPACA2_Cas9) and confirmed that Cas9 
expression did not alter the response to PI3K inhibition by BYL719 or the pan-PI3K inhibitor 
GDC0941 (Figures S1D-E).  
MIAPACA2_Cas9 cells were transduced with Avana4 lentiviral library (23,24). Cells 
were split into DMSO-, BYL719- or GDC0941-treated arms and passaged for 8 population 
doublings (Figure 1C). Cell proliferation rate was slowed by incubation with 10 μM BYL719 
or 1 μM GDC0941 (Figure 1D), concentrations at which PI3K signalling was near-
completely inhibited. Our choice of inhibitor concentration was driven by a balance of 
attaining near-complete pathway inhibition at a concentration that permits sufficient cell 
proliferation for the screen to be performed within approximately 3-4 weeks. Although the 
concentration of BYL719 used was quite high, we hypothesised that by using two chemically 
distinct inhibitors, off-target effects could be accounted for by focusing on hits observed with 
both inhibitors. Cells were harvested, genomic DNA (gDNA) extracted and sgRNAs 
amplified and barcoded by PCR. Next generation sequencing (NGS) was employed to 
quantify the abundance of each sgRNA in each experimental arm. This analysis 
demonstrated that sgRNAs targeting essential genes or KRAS, a known dependency of this 
cell line, were depleted from the population, whereas non-targeting sgRNAs were not 
(Figure S2A). The STARS algorithm (23,24) was used to rank genes with multiple scoring 
sgRNAs that were selectively depleted (enhancers of the antiproliferative effect) or enriched 
(suppressors of the antiproliferative effect) in each arm of the screen compared to DMSO 
(Figure 1E-F, Figure S2B-C and Tables S4-7).  
Overall, there was a large degree of overlap among the hit genes (false discovery 
rate (FDR) of <0.3) for which sgRNAs were depleted or enriched with BYL719 or GDC0941 
treatment (Figure 1G, Table S8). Out of 82 and 34 genes for which sgRNAs enhanced the 
anti-proliferative effect in the BYL719- and GDC0941-treated arms, respectively, 11 of the 
hits were common to both treatment arms (representation factor 75, p < 1.192 x 10-18). There 
was a greater degree of overlap between the genes for which sgRNAs were enriched with 
drug treatment, with 63 genes common to both drugs, out of a total of 135 and 120 genes 
that were enriched with BYL719 and GDC0941, respectively (representation factor of 74, p < 
6.147 x 10-109). Strikingly, sgRNAs targeting multiple negative regulators of PI3K/mTOR 
signalling were enriched in the drug-treated populations, implying that loss of these genes 
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promotes resistance to PI3K inhibition. Indeed, the top-ranking sgRNAs that were enriched 
in both drug-treated arms targeted TSC1 and TSC2, which inhibit the activity of RHEB and 
downstream mTORC1 signalling (36). Other sgRNAs enriched under drug treatment 
targeted PTEN, DDIT4 (36), AKT1S1 (37), and RALGAPB (38). Guide RNAs targeting 
genes encoding proteins of the mTORC1 network, mTOR kinase, RAPTOR and RRAGC 
were significantly depleted from the BYL719-treated arm, suggesting that loss of mTORC1 
sensitises cells to BYL719 treatment (39,40). This implicates the mTORC1 complex as a key 
mediator of resistance to PI3K inhibition. Given that loss of PTEN, TSC1 or TSC2 confers 
resistance to PI3K inhibition and loss of MTOR sensitizes to PI3K inhibition, this provides 
important validation of the screening conditions, as these events are known to modulate 
sensitivity to PI3K inhibitors (41,42).  
We used the Molecular Signatures Database (MSigDB) (31,32) to investigate the 297 
genes that modulated response to either BYL719 or GDC0941 and found enrichment for 
multiple pathways involved in PI3K signalling, including mTOR, AKT (PKB) and insulin 
signalling (Figure 1H). Multiple RTK signalling pathways, including the ERBB-family (in 
particular EGFR and ERBB2) as well as FGFR and PDGF, were enriched among the hit 
genes that were significantly enriched or depleted from the genome-wide CRISPR screen 
(FDR<0.3).  
‘Signalling by EGFR in cancer’ was the most highly enriched pathway and is of 
particular interest in pancreatic cancer as the EGFR inhibitor erlotinib has shown some 
modest activity in pancreatic cancer patients (43). Moreover, guides targeting genes 
associated with the internalisation and degradation of activated ERBB-family receptors were 
enriched in the drug-treated populations. Suppressor hit genes included AP2S1, AP2B1 and 
AP2M1, which encode subunits of the adaptor protein 2 (AP-2) complex and are involved in 
clathrin-dependent endocytosis of activated EGFR (44). We hypothesise that loss of the AP-
2 complex would result in sustained EGFR signalling. PRKACA encodes a catalytic subunit 
of protein kinase A (PKA) which phosphorylates and inhibits EGFR (45) and facilitates its 
internalisation and ubiquitination (46). Overall, loss of these genes may result in activation of 
EGFR, thereby promoting resistance to PI3K inhibition.   
Minipool validation screen further implicates RTK signalling as a modulator of 
sensitivity to PI3K inhibition in multiple cell lines.  
Penetrant synthetic lethal interactions, which demonstrate similar effects across 
diverse cellular models, may have greater therapeutic benefit as they could overcome the 
molecular heterogeneity that exists within tumours (47). Therefore, to prioritise penetrant 
synthetic lethal effects, we generated a minipool targeting 296 hit genes from the genome 
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wide screen, including those hits identified with either BYL719 or GDC0941, for a secondary 
validation screen. We tested this library in MIAPACA2 cells and in 3 additional KRAS-mutant 
pancreatic cancer cell lines. All cell lines chosen for the validation screen were of the QM 
subtype of PDAC as this represents the subtype with the poorest prognosis and therefore 
the most urgent clinical unmet need (48). We confirmed that Cas9 expression did not alter 
response to PI3K inhibition (Figure S3A). We selected concentrations of BYL719 and 
GDC0941 that inhibited PI3K signalling but still permitted cell proliferation (Figure S3B). 
Cells were then transduced with the minipool library. After puromycin selection, cells were 
treated with DMSO, BYL719 or GDC0941 and passaged for approximately 8 population 
doublings (Figure S4A). sgRNA abundance was determined as in the whole-genome 
screen. For each cell line, the abundance of non-targeting sgRNAs was not changed 
compared to the plasmid DNA, but sgRNAs targeting essential genes were depleted, 
indicating that transduction led to successful gene editing (Figure S4B).   
STARS analysis was used to prioritise genes with multiple top-scoring sgRNAs that 
were either enriched or depleted from the drug treated arms (Tables S9-24). To discover 
penetrant hits, genes were ranked according to their average STARS score across all 4 cell 
lines (Figure 2A). Reassuringly, there was considerable overlap between the hit genes that 
could modulate sensitivity to BYL719 and GDC0941. MEMO1, UBE2H, MIOS and YPEL5 
were the top four hit genes that, when lost, sensitised to both BYL719 and GDC0941 across 
all four cell lines. Targeting of PTEN, TSC1, TSC2, FRYL, PDCD10 and NF2 were the top 
six hit genes that drove resistance to both PI3K inhibitors. Notably, sgRNAs targeting 
KEAP1 were enriched in the presence of PI3K inhibition suggesting resistance could also be 
driven by NFE2L2/NRF2-mediated activation of an antioxidant stress response pathway 
(49). As STARS only uses the top 10% of sgRNAs to rank genes we also analysed the 
minipool screen based on the average LFC of all sgRNAs for each cell line and then ranked 
each gene in the minipool based on the average LFC across all cell lines. Reassuringly, both 
analysis approaches showed agreement (Figure S4C). We also confirmed that sgRNAs 
targeting the top-ranking genes identified in the primary screen also showed significant 
enrichment or depletion in the MIAPACA2 cell line in the secondary screen (Figure S4D). 
This suggested good concordance between the primary and secondary screens in 
MIAPACA2 cells.  
We focussed on two hits – MEMO1 and UBE2H, as they were both related to ERBB 
family signalling. Knockout of MEMO1 or UBE2H by CRISPR/Cas9 was confirmed (Figure 
2B) and enhanced the antiproliferative effect of BYL719 in PANC03.27 and MIAPACA2 
(Figure 2C). Both MEMO1 and UBE2H regulate signal transduction by the ERBB family and 
IGF1R (50,51); therefore, we hypothesised that stimulation of RTKs with specific ligands 
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  14 
could promote resistance to PI3K inhibition. Firstly, by culturing cells in low serum (0.1% 
FBS) AKT, PRAS40 and S6 phosphorylation were all decreased (Figure S5A), suggesting 
removal of growth factors could dampen signalling, even in the setting of oncogenic KRAS. 
Furthermore, co-treatment with BYL719 caused a near-complete suppression of AKT, 
PRAS40 and S6 phosphorylation. Low serum reduced cell proliferation by approximately 
50% relative to 10% serum as did treatment with BYL719 (Figure S5B). Low serum and 
BYL719 treatment modestly suppressed cell proliferation further but to a lesser degree 
compared to drug treatment in 10% serum. This may reflect either the reduced proliferation 
rate of the cells in low serum and/or a decrease in PI3K signalling under low serum 
conditions. Interestingly the addition of epidermal growth factor (EGF), heregulin (HRG) and 
insulin-like growth factor 1 (IGF1) significantly increased the GI50 concentration for BYL719 
(Figure 2D). HRG conferred the greatest degree of resistance to BYL719, associated with 
sustained AKT and S6 phosphorylation in the presence of BYL719 (Figure 2E). Notably, 
despite EGF strongly activating the EGFR receptor and causing the expected 
downregulation of EGFR expression (52), it was not as effective as HRG in driving 
resistance to BYL719. Taken together, these data suggest that the ERBB-family can drive 
resistance to PI3K inhibition in PDAC cells. 
Combination drug screen nominates clinically relevant inhibitors of ERBB and mTOR 
signalling as sensitizers to PI3K inhibition  
To identify clinically relevant inhibitors of RTK signalling that synergized with PI3K 
inhibition, we used an established library of 485 FDA approved drugs and tool compounds, 
alone and in combination with 10 μM BYL719 or 1 µM GDC0941. The library was screened 
in MIAPACA2 cells at a concentration of 800 nM, a concentration empirically chosen for a 
balance between being sufficient to modulate the target in cells but not so high as to induce 
off target effects. Nevertheless, some synergistic interactions may not be detected for those 
compounds which were used at a too high or too low concentration. The Bliss independence 
model (20) was used to calculate synergy for each drug combination (Tables S25-26). To 
identify hits common to both PI3K inhibitors, the Bliss score for BYL719 was plotted against 
that for GDC0941 (Figure 3A). The compounds were also ranked based on their average 
Bliss score for both PI3K inhibitors (Figure 3B). Notably, the ERBB family inhibitor pelitinib 
demonstrated greatest synergy with both PI3K inhibitors. Another ERBB family inhibitor, 
dacomitinib, also demonstrated synergy with both compounds. Multiple inhibitors of mTOR 
also ranked highly, including KU-0063794, rapamycin, ridaforolimus, everolimus and WYE-
354. KU-0063794 inhibits mTORC1 and mTORC2 kinase activity and, given that it drove 
greater synergy than mTORC1 allosteric inhibitors such as rapamycin, suggests that dual 
mTORC1/2 inhibitors may elicit greater synergy with PI3K inhibitors. The ERBB-family 
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inhibitor, pelitinib (53) and the mTORC1/2 kinase inhibitor, AZD2014 (54) were selected to 
validate the synergistic interaction between inhibition of PI3K and ERBB or mTOR signalling. 
The combination of BYL719 and pelitinib or AZD2014 synergistically inhibited proliferation of 
pancreatic cells in both short- (Figure 3C) and long-term (Figure 3D) assays. This 
highlighted the capacity of the ERRB-family and the mTOR pathway to drive resistance to 
PI3K inhibition.  
Using a spheroid co-culture of MIAPACA2 cells with activated pancreatic stellate 
cells (PSCs) — thought to better-model tumor-stromal interactions and the 3D tumor 
environment in vivo compared to 2D culture on plastic (55,56), the combination of BYL719 
and pelitinib or AZD2014 robustly inhibited spheroid growth (Figures 3E&F). Propidium 
iodide staining of spheroids after 4 days of treatment demonstrated a significant increase in 
dead or dying cells with the combination of BYL719 with either pelitinib or AZD2014 versus 
single agents (Figure 4G). Overall, we have clearly demonstrated that combined inhibition of 
PI3Kα and either ERBB or mTOR is synergistic in multiple models of PDAC.  
Resistance to PI3K inhibition is associated with sustained mTORC1 activity and can 
be overcome with mTOR and ERBB-family inhibitors 
The CRISPR and drug combination screens suggested that under PI3Kα inhibition, 
pancreatic cancer cells depend on mTOR signalling for proliferation. Therefore, we 
hypothesised that inadequate suppression of mTORC1 signalling underlies the resistance of 
pancreatic cells to BYL719. Indeed, phosphorylation of S6 (Ser240/244, catalysed by 
p70S6K) was not suppressed by BYL719 treatment in resistant PDAC cells, but was seen in 
the sensitive breast cancer cell line, T47D, whereas phospho-AKT was suppressed in both 
the sensitive and insensitive lines (Figure 4A). Moreover, while CRISPR-knockout of p110α 
decreased phosphorylation of AKT (Ser473) and PRAS40 (Thr246), phosphorylation of S6 
(Ser240/244) was maintained (Figure 4A). Across a panel of 12 pancreatic cell lines, the 
inhibition of phospho-S6 (Ser240/244) achieved with 10 μM BYL719 closely correlated with 
the effect on cell proliferation (Figure 4B). This suggests that mTOR signalling is uncoupled 
from PI3K in pancreatic cell lines and that this limits response to PI3Kα inhibition. Hence, we 
suggest that inhibition of phospho-S6 (Ser240/244) is an important and independent 
predictor of response to BYL719 versus other more proximal markers of PI3K signalling.  
Our results suggest that inhibition of PI3K alone does not inhibit proliferation and that 
combination with mTORC1 inhibition is required. However, clinical trials of allosteric mTOR 
inhibitors in pancreatic cancer have been unsuccessful likely due to loss of negative 
feedback on IRS1 (7,16) and, as shown herein, pancreatic cancer cells are resistant to 
single agent inhibition of mTORC1 in vitro (Figure S6A), despite suppression of S6 
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phosphorylation (Figure S6B). We propose that inhibition of both PI3K and mTORC1 
signalling is essential to inhibit cell proliferation. In line with this, the mTORC1/2 kinase 
inhibitors dactolisib (BEZ235) and AZD8055 (a closely-related analog of AZD2014) 
displayed potent antiproliferative activity in pancreatic cancer cell lines (Figure S6C&D) and 
this was associated with inhibition of phospho-S6 (Ser240/244) and at approximately 10-fold 
higher concentrations, inhibition of phospho-AKT (Ser473), as expected by dual inhibition of 
mTORC1 and mTORC2 (Figure S6E&F). 
We studied the effect of the combinations of BYL719 with pelitinib or AZD2014 on 
PI3K-mTOR signalling. BYL719 alone resulted in near-complete suppression of phospho-
AKT (Ser473) but decreases in phospho-S6 (Ser240/244) were not sustained. (Figure 4C, 
Figure S7A&B). Similarly, AZD2014 or pelitinib could not sustain inhibition of both PI3K-
AKT and mTORC1 signalling for 72 h. Only the combination of these agents with BYL719 
was sufficient to durably inhibit signalling at both nodes (Figure 4C, Figure S7A&B). Given 
that inhibition of ERBB signalling could also decrease MAPK pathway activity we also 
assessed the effect of pelitinib alone and in combination with BYL719 on ERK1/2 
phosphorylation. However, no robust inhibition was observed, suggesting that decreased 
MAPK pathway activity was not contributing to the antiproliferative activity of this 
combination (Figure S7B).  
Genetic alteration of the ERBB-PI3K signalling axis correlates with poor survival of 
PDAC patients 
To seek clinical relevance for our findings, we investigated how expression of 
selected genes, implicated by both our CRISPR and drug screens, related to clinical 
outcomes in PDAC by interrogating publicly available TCGA ‘provisional data’ in cBioPortal 
(57,58). 91% of patients in this dataset have KRAS-mutant tumours. Genetic alterations of 
the ERBB-family & PI3K signalling axis were present in 40% of 149 cases (Figure 5A) and 
associated with poor survival among PDAC patients, with a significant decrease in median 
survival from 23 months to 16 months (Figure 5B). Therefore, genetic alterations in the 
ERBB-family and PI3K signalling pathways are common in PDAC patients and may 
contribute to a poor clinical outcome. 
Discussion 
Overcoming acquired resistance to targeted therapies is arguably the major 
challenge facing drug discovery for the treatment of cancer. As exemplified by our CRISPR 
and drug combination screens, mechanisms of resistance to PI3K inhibition in PDAC 
converge on signalling through mTORC1. Incomplete suppression of mTORC1 underlies 
intrinsic resistance to PI3K inhibition and correlates with drug response. This was also 
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predictive of response to PI3Kα inhibition in cell lines and patient tumours in PI3K-dependent 
breast cancer (41). Taken together, this suggests that mTORC1 has utility as a biomarker of 
PI3K inhibition and loss of mTOR signalling, combined with PI3K inhibition, is necessary to 
inhibit tumour growth. Interestingly, a drug-modifier CRISPR screen with the KRAS inhibitor 
MRTX849 also identified MTOR depletion as an enhancer of drug activity and validated the 
combination of MRTX849 with everolimus and AZD2014. Consistent with our data, near-
complete suppression of phospho-S6 was associated with an anti-proliferative effect (6). 
Our data suggest that alternative pathways may compensate for PI3K inhibition to 
reactivate mTORC1. PI3K signalling is regulated by growth factors, as removal of FBS is 
sufficient to inhibit signalling through AKT and PRAS40 in PDAC cells. EGF confers 
resistance to BYL719 in head and neck cancer (62) and IGF1 and neuregulin 1 (also known 
as heregulin, HRG) drive resistance to PI3K inhibition in PIK3CA-mutant breast cancer (41). 
IGF1 is of interest in pancreatic cancer as it is found at high levels in tumour stroma (63). 
The greatest protective effect was associated with reactivation of PI3K signalling by HRG 
and suggests that ligand-mediated ERBB family activation participates in driving resistance 
to PI3K inhibition in PDAC, even in the context of oncogenic KRAS. 
Numerous regulators of RTK signalling were implicated in resistance to PI3K 
inhibition in both CRISPR screens. Of these, MEMO1 interacts with IGF1R and all four 
ERBB-family members (50,51) and mediates activation of MAPK and PI3K signalling (51). 
MEMO1 also interacts with IRS1 and prevents dephosphorylation and deactivation of IRS1 
signalling (50). UBE2H is involved in insulin and PI3K signalling in skeletal muscle and 
cooperates with the E3-ubiquitin ligase, Mitsugumin 53 (MG53 or TRIM72), to ubiquitinate 
and downregulate IRS1, which is important for negative feedback regulation of IGF1 and 
insulin signalling and inhibition of skeletal myogenesis (64). Loss of these genes sensitised 
cells to PI3K inhibition, demonstrating that RTK signalling is a clear determinant of response 
to PI3K inhibition.  
The combination drug screen suggested that targeting of mTOR or the ERBB-family 
could circumvent resistance to PI3K inhibition. The ERBB-family consists of four receptor 
tyrosine kinases, which are activated by ligand binding and regulate the RAS, MAPK and 
PI3K pathways. (65). However, KRAS is activated downstream of EGFR signalling, implying 
that EGFR may have little relevance in tumours driven by constitutively activated RAS 
signalling. In support of this, activating mutations in KRAS drive resistance to EGFR 
inhibitors in colorectal cancer (66,67). Conversely, in PDAC clinical trials, addition of the 
EGFR inhibitor, erlotinib, to gemcitabine resulted in a modest survival benefit, suggesting 
that tumours may still partially rely on EGFR signalling (43). In line with this, we show that 
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genetic alterations of ERBB and PI3K pathway members in PDAC patient tumours 
associates with poor survival and may provide potential patient selection criteria for this drug 
combination which warrants further investigation as a novel therapeutic strategy in PDAC. 
The use of gene expression signatures, to classify pancreatic cancers into distinct subtypes 
that exhibit vulnerabilities to specific drugs also has the potential to inform treatment 
decisions (48). For example, we focussed on the QM subtype of pancreatic cancer, so this 
patient population would be a rational choice for preliminary investigations. Furthermore, 
around 50% of clinical pancreatic samples are EGFR positive and overexpression correlates 
with poor survival (43). Upregulation of EGFR occurs selectively in PanINs and early stages 
of PDAC in mice (68,69), which implicates this receptor in tumour development. Moreover, 
mouse models show that Kras-driven tumorigenesis is dependent on Egfr, as genetic 
inactivation of Egfr blocks induction of PanINs and PDAC (68,69). Similarly, studies of 
KRAS-mutant NSCLC show that ERBB-family signalling amplifies the activity of mutant 
KRAS in in vivo models and loss of ERBB-family signalling impairs tumour development 
(70,71). Furthermore, studies conducted with the KRAS inhibitors AMG510 or MRTX849 
have shown synergistic antiproliferative activity with ERBB-family inhibitors (5,6). Studies in 
pancreatic organoid models have shown synergy between either MEK or AKT inhibitors 
when combined with ERBB-family inhibitors (but not with EGFR inhibition), underscoring the 
need to completely suppress ERBB signalling for activity (72). Pelitinib is a potent and 
irreversible EGFR inhibitor that also has activity against other ERBB family members, most 
notably HER2 (73,74). Therefore, the synergistic activity is likely not due to inhibition of 
EGFR alone, but through more durable inhibition of all ERBB-family receptors. These data 
clearly support a role for the ERBB-family in mutant KRAS signalling and KRAS-driven 
tumorigenesis and cell proliferation across tumour types.  
We have shown that pancreatic cancer cell lines are predominantly resistant to 
inhibition of PI3K via sustained mTOR signalling, despite effective inhibition of upstream 
PI3K signalling, indicating that alternative pathways can maintain mTORC1 activation and 
promote proliferation. Our genetic and pharmacological data show that dual inhibition of 
PI3K and mTORC1 signalling achieves greater antiproliferative activity than targeting a 
single node. Notably, dual mTORC1/2 kinase inhibitors such as AZD2014 achieve this at low 
nanomolar concentrations that are pharmacologically-relevant, whereas higher 
concentrations of mTORC1 allosteric inhibitors are required to achieve similar effects. This 
suggests a potential benefit of inhibiting both mTORC1 and mTORC2. Furthermore, this can 
also be achieved by combined inhibition of PI3K and ERBB-family signalling, indicating that 
the ERBB family is important for sustaining mTORC1 activity in the presence of PI3K 
inhibition, even in the context of mutant KRAS (Figure S8). Given the role of ERBB-family 
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activity in enhancing signalling through KRAS in NSCLC (70,71), one may speculate that 
inhibition of mTOR, downstream of ERBB-family inhibition, may result from attenuation of 
RTK-driven wildtype KRAS signalling (75). However, we did not detect robust inhibition of 
ERK phosphorylation in response to pelitinib (alone or with BYL719), suggesting this was 
not MAPK-dependent. This study provides the basis for future translational work in xenograft 
and genetically-engineered mouse models of pancreatic cancer, to determine the tolerability 
and efficacy of combined PI3K and mTOR kinase inhibitors or irreversible ERBB-family 
inhibitors. Reassuringly, the combination of PI3K and pan-ERBB inhibitors has been tested 
in KRAS or PIK3CA-driven xenografts and GEMMs confirming this therapeutic strategy is 
tolerated and efficacious in vivo (76-78). Our data suggest potential pharmacodynamic 
biomarkers to monitor drug response and guide dosing strategies. Positive results may 
renew interest in these classes of therapeutic agents for this challenging cancer type. 
Acknowledgments 
This work has been funded by The Institute of Cancer Research, Pancreatic Cancer UK and 
the Louis Nicholas Residuary Charitable Trust (to S.R. Whittaker). We thank Drs Muge 
Sarper and Amine Sadok at The Institute of Cancer Research for advice on the spheroid, co-
culture assays and Drs Mark Stubbs and Rosemary Burke, also at The Institute of Cancer 
Research, for access to the compound library and assistance with ECHO dispensing. 
 
   
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  20 
 
References 
1. Cancer Research UK Cancer Statistics for the UK. 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/. Accessed 
June 2018. 
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. 
Colorectal cancer. Lancet (London, England) 2010;375(9719):1030-47 doi 
10.1016/s0140-6736(10)60353-4. 
3. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, et al. Whole-
exome sequencing of pancreatic cancer defines genetic diversity and therapeutic 
targets. Nat Commun 2015;6:6744 doi 10.1038/ncomms7744. 
4. Collins MA, Bednar F, Zhang YQ, Brisset JC, Galban S, Galban CJ, et al. Oncogenic 
Kras is required for both the initiation and maintenance of pancreatic cancer in mice. 
J Clin Invest 2012;122(2):639-53 doi 10.1172/JCI59227. 
5. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical 
KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 
2019;575(7781):217-23 doi 10.1038/s41586-019-1694-1. 
6. Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The 
KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility 
of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov 
2020;10(1):54-71 doi 10.1158/2159-8290.CD-19-1167. 
7. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, et al. 
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic 
cancer: results of two phase II studies. BMC Cancer 2010;10:368 doi 10.1186/1471-
2407-10-368. 
8. Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, et al. Key role 
of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 
2010;16(20):4928-37 doi 10.1158/1078-0432.CCR-10-1210. 
9. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt 
signaling pathway is activated due to aberrant Pten expression and targets 
transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 
2004;23(53):8571-80 doi 10.1038/sj.onc.1207902. 
10. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. 
Oncogene 2008;27(41):5497-510 doi 10.1038/onc.2008.245. 
11. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, et 
al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an 
activated RAS oncogene to promote tumorigenesis. Mol Cell 2011;42(1):36-49 doi 
10.1016/j.molcel.2011.02.020. 
12. Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, et al. Targeting 
mTOR dependency in pancreatic cancer. Gut 2014;63(9):1481-9 doi 10.1136/gutjnl-
2013-306202. 
13. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, et al. Binding of ras to 
phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in 
mice. Cell 2007;129(5):957-68 doi 10.1016/j.cell.2007.03.051. 
14. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, et al. Selective 
requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell 
plasticity and cancer. Cancer Cell 2013;23(3):406-20 doi 10.1016/j.ccr.2013.01.023. 
15. Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schonhuber N, Planque L, et al. 
Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is 
completely dependent on wild-type PI 3-kinase p110alpha. Genes Dev 
2014;28(23):2621-35 doi 10.1101/gad.249409.114. 
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  21 
16. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. 
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic 
pancreatic cancer. J Clin Oncol 2009;27(2):193-8 doi 10.1200/JCO.2008.18.9514. 
17. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key 
effector of the oncogenic activation of the AKT and ERK signaling pathways that 
integrates their function in tumors. Cancer Cell 2010;18(1):39-51 doi 
10.1016/j.ccr.2010.05.023. 
18. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates 
survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient 
tumor cells. Cancer Cell 2005;8(4):287-97 doi 10.1016/j.ccr.2005.09.006. 
19. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A 
genome-scale RNA interference screen implicates NF1 loss in resistance to RAF 
inhibition. Cancer Discov 2013;3(3):350-62 doi 10.1158/2159-8290.CD-12-0470. 
20. Bliss CI. The Toxicity of poisons applied jointly. Annals of Applied Biology 
1939;26(3):585-615 doi 10.1111/j.1744-7348.1939.tb06990.x. 
21. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene 
expression signature associated with "K-Ras addiction" reveals regulators of EMT 
and tumor cell survival. Cancer Cell 2009;15(6):489-500 doi 
10.1016/j.ccr.2009.03.022. 
22. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for 
CRISPR screening. Nat Methods 2014;11(8):783-4 doi 10.1038/nmeth.3047. 
23. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. 
Optimized sgRNA design to maximize activity and minimize off-target effects of 
CRISPR-Cas9. Nat Biotechnol 2016;34(2):184-91 doi 10.1038/nbt.3437. 
24. Piccioni F, Younger ST, Root DE. Pooled Lentiviral-Delivery Genetic Screens. Curr 
Protoc Mol Biol 2018;121:32 1 1- 1 21 doi 10.1002/cpmb.52. 
25. Blomen VA, Majek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, et al. Gene 
essentiality and synthetic lethality in haploid human cells. Science 
2015;350(6264):1092-6 doi 10.1126/science.aac7557. 
26. Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. 
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific 
Cancer Liabilities. Cell 2015;163(6):1515-26 doi 10.1016/j.cell.2015.11.015. 
27. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification 
and characterization of essential genes in the human genome. Science 
2015;350(6264):1096-101 doi 10.1126/science.aac7041. 
28. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The 
Reactome Pathway Knowledgebase. Nucleic Acids Res 2018;46(D1):D649-D55 doi 
10.1093/nar/gkx1132. 
29. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new 
perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 
2017;45(D1):D353-D61 doi 10.1093/nar/gkw1092. 
30. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic 
Acids Res 2000;28(1):27-30. 
31. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 
Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27(12):1739-40 
doi 10.1093/bioinformatics/btr260. 
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. 
Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102(43):15545-50 
doi 10.1073/pnas.0506580102. 
33. Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, et al. 
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha 
inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 2013;23(13):3741-8 
doi 10.1016/j.bmcl.2013.05.007. 
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  22 
34. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification 
of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t 
hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor 
of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51(18):5522-32 
doi 10.1021/jm800295d. 
35. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. 
Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and 
development of the patient stratification strategy for clinical trials. Mol Cancer Ther 
2014;13(5):1117-29 doi 10.1158/1535-7163.MCT-13-0865. 
36. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard 
controlling cell growth. Biochem J 2008;412(2):179-90 doi 10.1042/BJ20080281. 
37. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al. 
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 
2007;25(6):903-15 doi 10.1016/j.molcel.2007.03.003. 
38. Martin TD, Chen XW, Kaplan RE, Saltiel AR, Walker CL, Reiner DJ, et al. Ral and 
Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, 
autophagy, and tumor cell invasion. Mol Cell 2014;53(2):209-20 doi 
10.1016/j.molcel.2013.12.004. 
39. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag 
complex targets mTORC1 to the lysosomal surface and is necessary for its activation 
by amino acids. Cell 2010;141(2):290-303 doi 10.1016/j.cell.2010.02.024. 
40. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, et al. 
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. 
Science 2008;320(5882):1496-501 doi 10.1126/science.1157535. 
41. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al. 
mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-
mutant breast cancer. Sci Transl Med 2013;5(196):196ra99 doi 
10.1126/scitranslmed.3005747. 
42. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of 
PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 
2015;518(7538):240-4 doi 10.1038/nature13948. 
43. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus 
gemcitabine compared with gemcitabine alone in patients with advanced pancreatic 
cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials 
Group. J Clin Oncol 2007;25(15):1960-6 doi 10.1200/JCO.2006.07.9525. 
44. Rappoport JZ, Simon SM. Endocytic trafficking of activated EGFR is AP-2 dependent 
and occurs through preformed clathrin spots. J Cell Sci 2009;122(Pt 9):1301-5 doi 
10.1242/jcs.040030. 
45. Barbier AJ, Poppleton HM, Yigzaw Y, Mullenix JB, Wiepz GJ, Bertics PJ, et al. 
Transmodulation of epidermal growth factor receptor function by cyclic AMP-
dependent protein kinase. J Biol Chem 1999;274(20):14067-73. 
46. Salazar G, Gonzalez A. Novel mechanism for regulation of epidermal growth factor 
receptor endocytosis revealed by protein kinase A inhibition. Mol Biol Cell 
2002;13(5):1677-93 doi 10.1091/mbc.01-08-0403. 
47. Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, et al. Identification 
of highly penetrant Rb-related synthetic lethal interactions in triple negative breast 
cancer. Oncogene 2018 doi 10.1038/s41388-018-0368-z. 
48. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of 
pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 
2011;17(4):500-3 doi 10.1038/nm.2344. 
49. Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, et al. Colorectal 
Tumors Require NUAK1 for Protection from Oxidative Stress. Cancer Discov 
2018;8(5):632-47 doi 10.1158/2159-8290.CD-17-0533. 
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  23 
50. Sorokin AV, Chen J. MEMO1, a new IRS1-interacting protein, induces epithelial-
mesenchymal transition in mammary epithelial cells. Oncogene 2013;32(26):3130-8 
doi 10.1038/onc.2012.327. 
51. Jiang K, Yang Z, Cheng L, Wang S, Ning K, Zhou L, et al. Mediator of ERBB2-driven 
cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the 
growth factor receptors IGF1R and ERBB2. J Biol Chem 2013;288(34):24590-9 doi 
10.1074/jbc.M113.467837. 
52. Heldin CH, Westermark B, Wasteson A. Desensitisation of cultured glial cells to 
epidermal growth factor by receptor down-regulation. Nature 1979;282(5737):419-20 
doi 10.1038/282419a0. 
53. Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, et al. Phase I 
study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in 
patients with advanced solid tumors. J Clin Oncol 2006;24(15):2252-60 doi 
10.1200/JCO.2005.01.8960. 
54. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, et al. 
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the 
discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013;23(5):1212-6 doi 
10.1016/j.bmcl.2013.01.019. 
55. Gaviraghi M, Tunici P, Valensin S, Rossi M, Giordano C, Magnoni L, et al. Pancreatic 
cancer spheres are more than just aggregates of stem marker-positive cells. Biosci 
Rep 2011;31(1):45-55 doi 10.1042/BSR20100018. 
56. Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, et al. 
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell 
2016;165(4):910-20 doi 10.1016/j.cell.2016.03.029. 
57. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio 
cancer genomics portal: an open platform for exploring multidimensional cancer 
genomics data. Cancer Discov 2012;2(5):401-4 doi 10.1158/2159-8290.CD-12-0095. 
58. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative 
analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci 
Signal 2013;6(269):pl1 doi 10.1126/scisignal.2004088. 
59. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire 
resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 
2010;468(7326):973-7 doi 10.1038/nature09626. 
60. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. 
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
Nature 2010;468(7326):968-72 doi 10.1038/nature09627. 
61. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. 
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen 
receptor blockade. Cell 2013;155(6):1309-22 doi 10.1016/j.cell.2013.11.012. 
62. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, et al. AXL 
mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis 
in head and neck and esophageal squamous cell carcinomas. Cancer Cell 
2015;27(4):533-46 doi 10.1016/j.ccell.2015.03.010. 
63. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth 
factor I overexpression in human pancreatic cancer: evidence for autocrine and 
paracrine roles. Cancer Res 1995;55(10):2007-11. 
64. Yi JS, Park JS, Ham YM, Nguyen N, Lee NR, Hong J, et al. MG53-induced IRS-1 
ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat 
Commun 2013;4:2354 doi 10.1038/ncomms3354. 
65. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell 
Biol 2001;2(2):127-37 doi 10.1038/35052073. 
66. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et 
al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N 
Engl J Med 2008;359(17):1757-65 doi 10.1056/NEJMoa0804385. 
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  24 
67. Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, et al. 
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in 
colorectal cancer. Nat Commun 2016;7:13665 doi 10.1038/ncomms13665. 
68. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. 
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal 
adenocarcinoma. Cancer Cell 2012;22(3):318-30 doi 10.1016/j.ccr.2012.08.001. 
69. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur 
PK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. 
Cancer Cell 2012;22(3):304-17 doi 10.1016/j.ccr.2012.07.024. 
70. Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, et al. The ERBB 
network facilitates KRAS-driven lung tumorigenesis. Sci Transl Med 2018;10(446) 
doi 10.1126/scitranslmed.aao2565. 
71. Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, et al. Afatinib 
restrains K-RAS-driven lung tumorigenesis. Sci Transl Med 2018;10(446) doi 
10.1126/scitranslmed.aao2301. 
72. Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, et al. Identification 
of Resistance Pathways Specific to Malignancy Using Organoid Models of 
Pancreatic Cancer. Clin Cancer Res 2019;25(22):6742-55 doi 10.1158/1078-
0432.CCR-19-1398. 
73. Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase 
activation and downstream signaling events in intact cells lacking epidermal growth 
factor receptor expression. Cancer Res 2007;67(3):1228-38 doi 10.1158/0008-
5472.CAN-06-3493. 
74. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. 
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-
3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine 
kinase activity of the epidermal growth factor receptor (EGFR) and the human 
epidermal growth factor receptor-2 (HER-2). J Med Chem 2003;46(1):49-63 doi 
10.1021/jm020241c. 
75. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in 
the regulation of mitogen-activated protein kinase signaling. Cancer Discov 
2013;3(1):112-23 doi 10.1158/2159-8290.CD-12-0231. 
76. Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, et al. Resistance to 
dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer 
models results in combined sensitivity to inhibition of the receptor tyrosine kinase 
EGFR. Sci Signal 2014;7(351):ra107 doi 10.1126/scisignal.2005516. 
77. Brady SW, Zhang J, Seok D, Wang H, Yu D. Enhanced PI3K p110alpha signaling 
confers acquired lapatinib resistance that can be effectively reversed by a 
p110alpha-selective PI3K inhibitor. Mol Cancer Ther 2014;13(1):60-70 doi 
10.1158/1535-7163.MCT-13-0518. 
78. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, et al. Conditional 
loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without 
affecting mammary tumor latency, gene expression, or signaling. Cancer Res 
2013;73(13):4075-85 doi 10.1158/0008-5472.CAN-12-4579. 
79. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, et al. Circulating 
Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. 
Gastroenterology 2019;156(1):108-18 e4 doi 10.1053/j.gastro.2018.09.022. 
80. San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, et al. Minimally 
invasive genomic and transcriptomic profiling of visceral cancers by next-generation 
sequencing of circulating exosomes. Ann Oncol 2016;27(4):635-41 doi 
10.1093/annonc/mdv604. 
 
  
on May 18, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 5, 2020; DOI: 10.1158/1535-7163.MCT-19-1131 
  25 
Figures 
 
Figure 1. A whole-genome CRISPR screen implicates receptor tyrosine kinase and 
mTOR signalling networks as modulators of response to PI3K inhibition. 
A. Proliferation of 14 human pancreatic cell lines (all KRAS-mutant except BxPC3) and one 
breast cancer cell line (T47D KRAS wildtype) was measured after incubation with increasing 
concentrations of BYL719 for 72 h. Proliferation was quantified using CellTiter-Blue and 
compound GI50 values were calculated using GraphPad Prism. Mean cell proliferation, 
relative to DMSO control, is plotted ± standard error (n=3).  
B. Phosphorylation of AKT and PRAS40 was assessed by Western blotting after incubation 
with increasing concentrations of BYL719 for 2 h, in the cell lines MIAPACA2, PANC1 and 
T47D (n=2). 
C. Overview of genome-wide CRISPR screening method. Cas9-expressing MIAPACA2 cells 
were infected with the Avana4 pooled CRISPR library and split into three arms. Cells were 
passaged for 8 population doublings in the presence of DMSO, BYL719 or GDC0941. The 
abundance of each sgRNA was assessed by next generation sequencing, under each 
condition.  
D. Following successful transduction of MIAPACA2_Cas9 cells with the Avana4 sgRNA 
library, cells were cultured in the presence of DMSO, 10 µM BYL719 or 1 µM GDC0941 for 
at least 8 population doublings. Cells were counted every 3-5 d and population doublings are 
the mean of four replicates ± SE. 
E. The average log-fold change (LFC) in sgRNA abundance was determined for BYL719-
treated samples versus the DMSO controls. STARS analysis was used to rank genes that 
when targeted by CRISPR, enhanced the antiproliferative activity of BYL719. 
F. STARS analysis was used as in E to rank genes that when targeted by CRISPR, 
suppressed the antiproliferative activity of BYL719 and conferred resistance to the drug. 
G. Venn diagram analysis of hit genes to identify shared enhancers/suppressors of BYL719 
and GDC0941 activity. 
H. GSEA highlights key pathways that modulate sensitivity to PI3K inhibition. Significantly 
enriched pathways from the Reactome and KEGG databases were nominated from a list of 
the hit genes (FDR < 0.3) that were enriched or depleted in the genome-wide CRISPR 
screen with either BYL719 or GDC0941. 
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Figure 2. The ERBB-family can sustain pancreatic cancer cell proliferation and 
mediate resistance to PI3K inhibition associated with S6 phosphorylation. 
A. A secondary screen of top-ranking hits from the primary screen was conducted in 
MIAPACA2, PANC1, PATU8902 and PANC03.27 cells treated with BYL719 or GDC0941. 
For each cell line, STARS analysis was used to rank genes that enhanced or suppressed 
the antiproliferative activity of BYL719 or GDC0941. Genes were then ranked according to 
the mean STARS score across all four cell lines. Genes with a STARS score of 4 or more in 
3 or more cell lines are highlighted in red. Grey boxes indicate the gene was not ranked by 
STARS.  
B. PANC03.27 and MIAPACA2 cells expressing Cas9 were transduced with lentiviral vectors 
encoding sgRNAs targeting GFP, UBE2H or MEMO1 to generate cell populations with 
reduced expression of either UBE2H or MEMO1. Cells were lysed 7 d after transfection and 
cell lysates were analyzed by Western blotting (n=3). 
C. Cells as in B were treated with increasing concentrations of BYL719 or GDC0941. After 4 
d of drug treatment, cell proliferation was quantified using CellTiter-Blue. Mean cell 
proliferation, relative to the DMSO treated control is plotted ± SE (n=3).  
D. PATU8988S cells were cultured in the presence of BSA, EGF, HRG or IGF1 (100 ng/ml) 
with 10% FBS and treated with a range of concentrations of BYL719. Cell proliferation was 
quantified after 72 h using CellTiter-Blue. The mean GI50 is plotted ± SE (n=6) and statistical 
significance compared to the BSA control was determined by one-way ANOVA. 
E. PATU8988S cells were cultured in the presence of BSA, EGF, HRG or IGF1 (100 ng/ml) 
with 10% FBS and treated with DMSO (0.1 %) or BYL719 (2 μM) for 72 h. Cell lysates were 
analyzed by Western blotting (n=3). 
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Figure 3. A combinatorial drug screen identifies mTOR and ERBB-family inhibitors as 
potent enhancers of PI3K inhibition. 
A. MIAPACA2 cells were treated with a library of 487 FDA-approved drugs and tool 
compounds at a concentration of 800 nM in the presence or absence of 10 µM BYL719 or 1 
µM GDC0941. After 96 h, cell proliferation was quantified by CellTiter-Blue assay. 
Proliferation was normalized to a DMSO-treated control on each plate and the Bliss 
independence model was used to calculate synergy with BYL719 or GDC0941 for each of 
the compounds in triplicate. The mean Bliss score for each compound in combination with 
BYL719 was plotted against the mean Bliss score for each compound in combination with 
GDC0941. 
B. The mean Bliss score for each compound in combination with BYL719 and GDC0941 
was calculated and used to rank compounds. The top 20 compounds are shown. 
C. Cells were incubated with a matrix of increasing concentrations of BYL719 and either 
pelitinib or AZD2014 for 144 h. Cell viability was measured using CellTiter-Blue and 
normalized to DMSO-treated wells (a shift from blue to red indicates loss of proliferation). 
The Bliss independence model was used to calculate synergy where a shift from green to 
red indicates increasing synergy (n=3). 
D. Cells were incubated with the indicated compounds or the combinations in triplicate for 14 
d. Cells were fixed and stained with 0.5 % crystal violet. 
E. Spheroids consisting of a co-culture of MIAPACA2 cells and PSCs (1:1) were allowed to 
establish for 24 h and were then treated with the indicated compounds or the combination 
for 9 d. Dual calcein AM (viable cells) and propidium iodide (non-viable cells) staining was 
performed. Images were obtained using the Celigo imaging cytometer. 
F. The diameter of the spheroid was measured every 3-4 d by quantification of images 
recorded on the Celigo. Colony diameter is plotted as the mean of at least three independent 
spheroids ± SE (n=2). Statistical significance was determined by one-way ANOVA with 
Tukey’s multiple comparisons test. 
G. Propidium iodide staining of spheroids was performed after 4 d and fluorescence intensity 
of the spheroid was quantified on the Celigo (n=6). Mean fluorescence intensity is 
represented by the horizontal bar. Statistical significance was determined by one-way 
ANOVA with Tukey’s multiple comparisons test. 
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Figure 4. Inhibition of S6 phosphorylation is associated with synergistic, 
antiproliferative effects of combined PI3K and mTOR or pan-ERBB family inhibition. 
A. MIAPACA2 and T47D cells were exposed to the indicated concentrations of BYL719 for 2 
h or MIAPACA2_Cas9 cell clones lacking expression of p110 (knocked out via CRISPR-
Cas9) were analysed by Western blotting for PI3K pathway activation using the indicated 
antibodies. NIC: no-infection control. 
B. Percentage cell proliferation after incubation with 10 μM BYL719 for 72 h relative to 
DMSO (n=3) is plotted against percentage S6 phosphorylation, relative to DMSO, quantified 
from Western blots after incubation with 10 μM BYL719 for 2 h (n=2). Each point represents 
a different cell line from a panel of 12 PDAC cells. Linear regression analysis in GraphPad 
Prism was used to determine the correlation between the two variables. 
C. MIAPACA2 cells were incubated with DMSO (0.1 %) BYL719 (10 μM), AZD2014 (250 
nM), pelitinib (1 μM), or the indicated combinations for 72 h and cell lysates were analyzed 
by Western blotting (n=2). 
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Figure 5. Alterations in genes encoding the ERBB-family and selected downstream 
signalling mediators is associated with reduced pancreatic cancer patient survival. 
A. Genetic alteration of the ERBB–PI3K signalling axis was assessed using cBioPortal and 
the TCGA ‘provisional dataset’ for 149 pancreatic cancer patients. 60 of 149 patients (40 %) 
displayed alterations in one or more of the indicated genes. 
B. Overall survival of pancreatic cancer patients with or without genetic alterations of the 
genes shown in A. Significance was assessed by Log-rank Mantel-Cox test. 
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